Modeling the interactions between osteoblast and osteoclast activities in bone remodeling
- PMID: 15234198
- DOI: 10.1016/j.jtbi.2004.03.023
Modeling the interactions between osteoblast and osteoclast activities in bone remodeling
Abstract
We propose a mathematical model explaining the interactions between osteoblasts and osteoclasts, two cell types specialized in the maintenance of the bone integrity. Bone is a dynamic, living tissue whose structure and shape continuously evolves during life. It has the ability to change architecture by removal of old bone and replacement with newly formed bone in a localized process called remodeling. The model described here is based on the idea that the relative proportions of immature and mature osteoblasts control the degree of osteoclastic activity. In addition, osteoclasts control osteoblasts differentially depending on their stage of differentiation. Despite the tremendous complexity of the bone regulatory system and its fragmentary understanding, we obtain surprisingly good correlations between the model simulations and the experimental observations extracted from the literature. The model results corroborate all behaviors of the bone remodeling system that we have simulated, including the tight coupling between osteoblasts and osteoclasts, the catabolic effect induced by continuous administration of PTH, the catabolic action of RANKL, as well as its reversal by soluble antagonist OPG. The model is also able to simulate metabolic bone diseases such as estrogen deficiency, vitamin D deficiency, senescence and glucocorticoid excess. Conversely, possible routes for therapeutic interventions are tested and evaluated. Our model confirms that anti-resorptive therapies are unable to partially restore bone loss, whereas bone formation therapies yield better results. The model enables us to determine and evaluate potential therapies based on their efficacy. In particular, the model predicts that combinations of anti-resorptive and anabolic therapies provide significant benefits compared with monotherapy, especially for certain type of skeletal disease. Finally, the model clearly indicates that increasing the size of the pool of preosteoblasts is an essential ingredient for the therapeutic manipulation of bone formation. This model was conceived as the first step in a bone turnover modeling platform. These initial modeling results are extremely encouraging and lead us to proceed with additional explorations into bone turnover and skeletal remodeling.
Similar articles
-
Parathyroid hormone temporal effects on bone formation and resorption.Bull Math Biol. 2000 Jan;62(1):163-88. doi: 10.1006/bulm.1999.0146. Bull Math Biol. 2000. PMID: 10824426
-
Morphology and biochemistry of bone remodeling: possible control by vitamin D, parathyroid hormone, and other substances.Lab Invest. 1988 Oct;59(4):418-42. Lab Invest. 1988. PMID: 3050272 Review.
-
The skeleton in primary hyperparathyroidism: a review focusing on bone remodeling, structure, mass, and fracture.APMIS Suppl. 2001;(102):1-52. APMIS Suppl. 2001. PMID: 11419022 Review.
-
A theoretical model for simulating effect of parathyroid hormone on bone metabolism at cellular level.Mol Cell Biomech. 2009 Jun;6(2):101-12. Mol Cell Biomech. 2009. PMID: 19496258
-
Mathematical model of paracrine interactions between osteoclasts and osteoblasts predicts anabolic action of parathyroid hormone on bone.Endocrinology. 2005 Aug;146(8):3589-95. doi: 10.1210/en.2004-1642. Epub 2005 Apr 28. Endocrinology. 2005. PMID: 15860557
Cited by
-
The kinetics of vitamin D₃ in the osteoblastic cell.Bull Math Biol. 2013 Sep;75(9):1612-35. doi: 10.1007/s11538-013-9861-2. Epub 2013 Jun 18. Bull Math Biol. 2013. PMID: 23775045 Free PMC article.
-
Mechanobiochemical bone remodelling around an uncemented acetabular component: influence of bone orthotropy.Med Biol Eng Comput. 2024 Jun;62(6):1717-1732. doi: 10.1007/s11517-024-03023-0. Epub 2024 Feb 14. Med Biol Eng Comput. 2024. PMID: 38353834
-
Low-level laser therapy enhances the expression of osteogenic factors during bone repair in rats.Lasers Med Sci. 2014 Jan;29(1):147-56. doi: 10.1007/s10103-013-1302-9. Epub 2013 Mar 21. Lasers Med Sci. 2014. PMID: 23515631
-
Predicting nonlinear changes in bone mineral density over time using a multiscale systems pharmacology model.CPT Pharmacometrics Syst Pharmacol. 2012 Nov 14;1(11):e14. doi: 10.1038/psp.2012.15. CPT Pharmacometrics Syst Pharmacol. 2012. PMID: 23835796 Free PMC article.
-
Application of a mechanism-based disease systems model for osteoporosis to clinical data.J Pharmacokinet Pharmacodyn. 2013 Apr;40(2):143-56. doi: 10.1007/s10928-012-9294-9. Epub 2013 Jan 12. J Pharmacokinet Pharmacodyn. 2013. PMID: 23315144 Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
